Why Niagen Bioscience, Inc.’s (NAGE) Stock Is Down 6.77%
As of Thursday, July 23, Niagen Bioscience, Inc.’s NAGE share price has dipped by 6.77%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Cynthia McLaughlin
Rosalio Madrigal
Michael Rose
Jenna Brashear
Jenna Brashear
| Share Statistics | NAGE | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $271.4 | $337.9 | 31% |
|
| Shares Out (Mil) | 84.6 | 27.3 | 59% |
|
| Institutional Ownership | 67.2% | 55.3% | 42% |
|
| Float (Mil) | 59.6 | 30.7 | 51% |
|
| Beta | 2.06 | 0.56 | 93% |
|
| Avg Daily Volume (000s) | 626 | 150 | 63% |
|
| Price Change (52-week) |
(64.3%) | 56.7% | 11% |
|
| Growth | NAGE | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 16.9% | 2.3% | 77% |
|
| Net Income (5yr) | 23.5% | (4.8%) | 78% |
|
| EPS (5yr) | 21.2% | 2.3% | 70 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 59.5% | (13.2%) | 95% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | ($0.010) | $0.190 | $0.290 | |
| Month Ago EPS | ($0.010) | $0.190 | $0.290 | |
| # Rev Up | 1 | 1 | 0 | |
| # Rev Down | 1 | 0 | 1 | |
| Three Months Ago EPS | $0.030 | $0.240 | $0.320 | |
| Year/Year Chg | (114.3%) | (5.0%) | 120.0% | |
| Financials | NAGE | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $130 | $421 | 29% |
|
| Net Income (TTM) (Mil) | $19 | $0 | 49% |
|
| EPS (TTM) | $0.234 | $0.100 | 48% |
|
| Operating Cash Flow (TTM) (Mil) | $4 | $12 | 36% |
|
| Net Cash Flow (TTM) (Mil) | $11 | $0 | 58% |
|
| Long-Term Debt (Q1) (Mil) | $2 | $44 | 19% |
|
| Enterprise Value (Q1) (Mil) | $216 | $334 | 27% |
|
| Valuation | NAGE | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.30 | 2.05 | 68% |
|
| P/E | 16.2 | 16.4 | 40% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 0.8 | 0.7 | 36% |
|
| Ratios | NAGE | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 64.3% | 64.3% | 76% |
|
| Net Margin | 14.3% | 1.6% | 72% |
|
| ROA | 19.0% | 1.3% | 96% |
|
| ROE | 27.1% | 5.3% | 86% |
|
| Liabilities to Assets | 28.0% | 48.0% | 20% |
|
| F-Score | 5 | 4 | 51% |
|
Niagen Bioscience, Inc. did not pass any screens on 7/31/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors